Abstract:IntroductionFactors implicated in influenza-mediated morbidity and mortality include robust cytokine production (cytokine storm), excessive inflammatory infiltrates, and virus-induced tissue destruction. Tumor necrosis factor-alpha (TNF-α) is an important pro-inflammatory cytokine present during influenza infection, but it is unclear whether direct inhibition of TNF-α can elicit protection against influenza infection.MethodsIn this study, the commercially available TNF-α inhibitor etanercept was used to inhibit TNF-α induced by lethal A/FM/1/47 (H1N1) influenza virus infection of mice. The effects of TNF-α inhibition on mouse survival, pathologic changes, immune cell infiltration, inflammatory cytokine secretion, Toll-like receptor expression, and activation of the NF-κB (nuclear factor kappa B) signaling pathway were evaluated.ResultsThe intranasal delivery of etanercept provided significant protection against mortality (30% of mice survived up to 14 days after infection) in mice treated with etanercept. In contrast, no survivors were found beyond 6 days in mice treated with saline after lethal challenge with H1N1 influenza virus. It was observed that etanercept significantly reduced inflammatory cell infiltration (for example, macrophages and neutrophils), inflammatory cytokine secretion (for example, interleukin-6, TNF-α, and interferon gamma), and expression of Toll-like receptors (TLR-3, TLR-4, and TLR-7). Etanercept also downregulated and inhibited the cascade proteins of the NF-κB signaling pathway (for example, MyD88, TRIF, NF-κB, and p65), as well as enhanced host control of virus replication.ConclusionsThese findings indicate that etanercept, by blocking TNF-α, can significantly downregulate excessive inflammatory immune responses and provide protection against lethal influenza infection, making its use a novel strategy for controlling severe influenza-induced viral pneumonia.

High Expression of Recombinant Human Catalase and Its Immunomodulatory Effects on H1N1 Influenza Virus Infection

PEGylated Human Catalase Elicits Potent Therapeutic Effects on H1N1 Influenza-Induced Pneumonia in Mice

Ability of Recombinant Human Catalase to Suppress Inflammation of the Murine Lung Induced by Influenza A

Therapeutic Effect of Recombinant Human Catalase on H1N1 Influenza-Induced Pneumonia in Mice.

High-level expression and purification of recombinant human catalase in Pichia pastoris.

Expression and purification and of human hydrogen peroxidase in E.coli and identification of its biological activity

[Construction and expression of recombinant adenovirus containing human catalase gene in vitro].

Evaluation of Panel of Neutralising Murine Monoclonal Antibodies and a Humanised Bispecific Antibody Against Influenza A(H1N1)pdm09 Virus Infection in a Mouse Model.

Superoxide Dismutase Prevents SARS-CoV-2-Induced Plasma Cell Apoptosis and Stabilizes Specific Antibody Induction

Maternally transmitted milk containing recombinant human catalase provides protection against oxidation for mouse offspring during lactation.

RSM optimization of HSA/IL1Ra in Pichia pastoris overexpression strain and study of its in vivo activity in reducing hyperglycemia of GK rats.

Catalpol inhibits inflammatory response in rat alveolar macrophages infected with influenza virus by downregulating TLR 7 , MyD 88 , NF-κB , and PLA 2

A Novel Catalase Nanogels for Effective Treatment of Neutrophilic Asthma

Novel, Real-Time Cell Analysis for Measuring Viral Cytopathogenesis and the Efficacy of Neutralizing Antibodies to the 2009 Influenza A (h1n1) Virus

Generation, Characterization and Epitope Mapping of Two Neutralizing and Protective Human Recombinant Antibodies Against Influenza A H5N1 Viruses.

Potent prophylactic and therapeutic efficacy of recombinant human ACE2-Fc against SARS-CoV-2 infection in vivo

Inhibition of the inflammatory cytokine tumor necrosis factor-alpha with etanercept provides protection against lethal H1N1 influenza infection in mice

Enzymatization of mouse monoclonal antibodies to the corresponding catalytic antibodies

An Antioxidant Enzyme Therapeutic for COVID‐19

Preparation and Identification of the Fusion Protein and the Polyclonal Antibody of GTF Catalytic Region from S.sobrinus

Protection Against Influenza H7n9 Virus Challenge with A Recombinant Np-M1-Hsp60 Protein Vaccine Construct in Balb/C Mice